A phase IIb study of Minerval (2OHOA) in patients with Glioblastoma multiforme
Phase of Trial: Phase II
Latest Information Update: 21 Jan 2018
At a glance
- Drugs 2-hydroxyoleic acid (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- 21 Jan 2018 According to a Lipopharma media release, if the results of this clinical trial are positive, Lipopharma plans to apply for a conditional approval of 2OHOA in Europe for the treatment of newly diagnosed GBM patients, in combination with radiotherapy and temozolomide.
- 25 Nov 2015 New trial record
- 23 Nov 2015 According to Lipopharma media release, company is opening a fund raising campaign to conduct this trial and if successful then it could could lead to a conditional approval in Europe for the treatment of newly-diagnosed GBM in combination with radiotherapy and temozolomide.